US5763596A
(en)
*
|
1989-09-15 |
1998-06-09 |
Metabasis Therapeutics, Inc. |
C-4' modified adenosine kinase inhibitors
|
US5864033A
(en)
*
|
1989-09-15 |
1999-01-26 |
Metabasis Therapeutics, Inc. |
Adenosine kinase inhibitors
|
US5721356A
(en)
*
|
1989-09-15 |
1998-02-24 |
Gensia, Inc. |
Orally active adenosine kinase inhibitors
|
US5763597A
(en)
*
|
1989-09-15 |
1998-06-09 |
Metabasis Therapeutics, Inc. |
Orally active adenosine kinase inhibitors
|
US5726302A
(en)
*
|
1989-09-15 |
1998-03-10 |
Gensia Inc. |
Water soluble adenosine kinase inhibitors
|
US5795977A
(en)
*
|
1989-09-15 |
1998-08-18 |
Metabasis Therapeutics, Inc. |
Water soluble adenosine kinase inhibitors
|
US5674998A
(en)
*
|
1989-09-15 |
1997-10-07 |
Gensia Inc. |
C-4' modified adenosine kinase inhibitors
|
ATE159257T1
(en)
*
|
1994-05-03 |
1997-11-15 |
Ciba Geigy Ag |
PYRROLOPYRIMIDE DERIVATIVES WITH ANTIPROLIFERATIVE EFFECT
|
US5665721A
(en)
*
|
1995-06-07 |
1997-09-09 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
US6395733B1
(en)
|
1995-06-07 |
2002-05-28 |
Pfizer Inc |
Heterocyclic ring-fused pyrimidine derivatives
|
US6143749A
(en)
*
|
1995-06-07 |
2000-11-07 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
WO1997003084A1
(en)
*
|
1995-07-11 |
1997-01-30 |
Astra Pharmaceuticals Ltd. |
New inhibitors of platelet aggregation
|
JP4275733B2
(en)
*
|
1996-01-23 |
2009-06-10 |
ノバルティス アクチエンゲゼルシャフト |
Pyrrolopyrimidine and process for producing the same
|
JP4255138B2
(en)
*
|
1996-05-24 |
2009-04-15 |
湧永製薬株式会社 |
Brain disease treatment
|
AU3255097A
(en)
*
|
1996-07-05 |
1998-02-02 |
Novo Nordisk A/S |
Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
|
US5824657A
(en)
*
|
1997-03-18 |
1998-10-20 |
Cubist Pharmaceuticals, Inc. |
Aminoacyl sulfamides for the treatment of hyperproliferative disorders
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
US5866574A
(en)
*
|
1997-04-10 |
1999-02-02 |
Kyowa Hakko Kogyo Co., Ltd. |
Pancreatitis remedy
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
BR9913887A
(en)
*
|
1998-09-18 |
2001-10-23 |
Basf Ag |
Compound, and, methods of inhibiting protein kinase activity, treating a patient who has a condition that is mediated by protein kinase activity and decreasing fertility in a patient
|
TWI229674B
(en)
|
1998-12-04 |
2005-03-21 |
Astra Pharma Prod |
Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
PL354249A1
(en)
|
1999-09-17 |
2003-12-29 |
Abbott Gmbhabbott Gmbh |
Pyrazolopyrimidines as therapeutic agents
|
EP1250128A2
(en)
*
|
1999-12-16 |
2002-10-23 |
Alcon, Inc. |
Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
|
WO2001072751A1
(en)
*
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
GB0100622D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds V111
|
GB0100623D0
(en)
*
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds IV
|
DE10238722A1
(en)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
|
DE10238724A1
(en)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
|
WO2004092177A1
(en)
|
2003-04-09 |
2004-10-28 |
Biogen Idec Ma Inc. |
Triazolopyrazines and methods of making and using the same
|
US7285550B2
(en)
|
2003-04-09 |
2007-10-23 |
Biogen Idec Ma Inc. |
Triazolotriazines and pyrazolotriazines and methods of making and using the same
|
DE602004018637D1
(en)
|
2003-04-09 |
2009-02-05 |
Biogen Idec Inc |
A2A adenosine receptor antagonistic
|
AR049384A1
(en)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
PURINA DERIVATIVES
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
AU2007347115A1
(en)
|
2006-04-04 |
2008-10-23 |
The Regents Of The University Of California |
PI3 kinase antagonists
|
CN101842008A
(en)
*
|
2007-08-02 |
2010-09-22 |
南方研究所 |
5 '-be substituted adenosine, its preparation and as the purposes of S adenosylmethionine decarboxylase inhibitor
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
JP5498392B2
(en)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1,5-Dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators for the treatment of CNS disorders
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240452B1
(en)
|
2008-01-04 |
2019-05-29 |
Intellikine, LLC |
1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
|
HUE041598T2
(en)
|
2008-01-18 |
2019-05-28 |
Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic |
Novel cytostatic 7-deazapurine nucleosides
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
JP5547099B2
(en)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
Kinase inhibitors and methods of use
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
GB0815968D0
(en)
*
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
PE20110383A1
(en)
|
2008-09-08 |
2011-07-15 |
Boehringer Ingelheim Int |
PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A)
|
JP5731978B2
(en)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
Heterocyclic kinase inhibitor
|
AU2009305669A1
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
EA201190178A1
(en)
*
|
2009-03-20 |
2012-06-29 |
Алиос Биофарма, Инк. |
REPLACED NUCLEOSIDE AND NUCLEOTIC ANALOGUES
|
KR20120003868A
(en)
|
2009-03-31 |
2012-01-11 |
베링거 인겔하임 인터내셔날 게엠베하 |
1-heterocyclyl-1,5-dyhydro-pyrazolo[3,4-d]pyrimidine-4-one derivatives and their use as pde9a modulators
|
NZ700583A
(en)
*
|
2009-04-22 |
2016-04-29 |
Acad Of Science Czech Republic |
Novel 7-deazapurine nucleosides for therapeutic uses
|
JP5789252B2
(en)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
Heterocyclic compounds and uses thereof
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
AU2011255218B2
(en)
|
2010-05-21 |
2015-03-12 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
BR112013003097B1
(en)
|
2010-08-12 |
2021-03-16 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones and pharmaceutical composition
|
US8871737B2
(en)
|
2010-09-22 |
2014-10-28 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
CN106619647A
(en)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
Combination of mtor inhibitors and pi3-kinase inhibitors and uses thereof
|
MX2014000648A
(en)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof.
|
CN103930422A
(en)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
Heterocyclic compounds and uses thereof
|
AR091790A1
(en)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
EP2794630A4
(en)
|
2011-12-22 |
2015-04-01 |
Alios Biopharma Inc |
Substituted phosphorothioate nucleotide analogs
|
US8916538B2
(en)
|
2012-03-21 |
2014-12-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
JP2015532287A
(en)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
IRE1 regulation
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG10201902074UA
(en)
|
2013-10-04 |
2019-04-29 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2014277740B1
(en)
*
|
2014-12-17 |
2016-02-25 |
Institute of Organic Chemistry and Biochemistry, ASCR, v.v.i. |
Novel substituted 7-deazapurine ribonucleosides for therapeutic uses
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
CN110022881B
(en)
*
|
2016-11-18 |
2023-05-02 |
艾库斯生物科学有限公司 |
Inhibitors of CD 73-mediated immunosuppression
|
CN110687232A
(en)
*
|
2018-07-04 |
2020-01-14 |
郑州泰丰制药有限公司 |
Method for detecting L-chloro-sugar epimer by high performance liquid chromatography
|
US20220152072A1
(en)
*
|
2019-04-05 |
2022-05-19 |
Prelude Therapeutics, Incorporated |
Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
|
WO2024134541A1
(en)
*
|
2022-12-20 |
2024-06-27 |
iTeos Belgium SA |
Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
|